In the setting of acute coronary syndromes, rivoraxaban (2.5 mg twice daily, a quarter of the dose used for stroke prevention in atrial fibrillation) reduced a composite endpoint of death from cardiovascular causes, myocardial infarction, or stroke and demonstrated a survival benefit when added to standard of care (that largely included aspirin and P2Y12 antagonism) [43]. The gene discussed is P2RY12; the disease is atrial fibrillation.